Maravai LifeSciences Holdings, Inc. - Class A common stock — Bilan (NASDAQ:MRVI) | MetaTrader

Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques

Trimestriel Annuel

Total de l'actif 1.92 B2.28 B1.49 B1.01 B770.58 M Total du passif 1.37 B1.38 B697.57 M431.04 M397.87 M Total des capitaux propres 545.36 M905.24 M789.88 M577.21 M372.71 M Total du passif et des capitaux propres 1.92 B2.28 B1.49 B1.01 B770.58 M Dette totale 524.59 M522 M518.71 M290.49 M292.74 M Dette nette 524.59 M522 M518.71 M290.49 M69.44 M

Nouvelles

Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)

Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript

Maravai : une hausse de 41 % du chiffre d’affaires au T1 2026 ramène la rentabilité

Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates

All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy

Baxter International (BAX) Tops Q1 Earnings and Revenue Estimates

Maravai LifeSciences Holdings, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:MRVI) 2026-02-26

Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q4 Loss, Beats Revenue Estimates

Maravai T4 2025 : retour à un EBITDA positif grâce aux réductions de coûts

Maravai Q4 2025 slides: return to positive EBITDA on cost cuts

Maravai Lifesciences earnings beat by $0.03, revenue topped estimates

Maravai LifeSciences génère un rendement de 60% après l’alerte de juste valeur en mars